Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what estimate he has made of the number of lung cancer patients who would benefit from the immunotherapy nivolumab; and if he will make a statement.

NHS England has advised that it is not currently possible to estimate the numbers of patients in England who will be suitable for treatment, as the licence for nivolumab has been split into two distinct sub-groups (squamous and non-squamous non-small cell lung cancer) and the latter has yet to receive a marketing authorisation.